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Infectious diseases of the nervous system
in the developing world have been rela-
tively neglected. This is paradoxical be-
cause neurotropic pathogens are common
and contribute significantly to human
suffering and disease burden in these
regions. Clearly, living with a neurological
handicap and/or cognitive dysfunction
may have a strong negative impact on
socioeconomic development. Here, we
briefly describe a few examples of such
infections causing severe diseases that
result in the loss of motor-sensory function
(cerebral malaria, viral encephalitis), alter-
ations of cognition/behavior (AIDS), or
sleep perturbations (African trypanosomi-
asis). Importantly, there is an opportunity
to interfere with infection because the
central nervous system (CNS) is not
usually the primary site for pathogen
infection.
Cerebral Malaria
Cerebral malaria (CM) is one of the
most severe complications of Plasmodium
falciparum malaria. It is most common in
young children living in malaria-endemic
sub-Saharan Africa where CM incidence
is 1–12 cases/1,000 children per year and
the mortality rate can be as high as 22%,
as described recently in a large cohort of
Kenyan children (,14 years old) [1].
Malaria was found to be associated with
neurological involvement on admission in
nearly half of the patients (with an
incidence of 47.6%), and their mortality
was increased when compared to malaria
patients without neurological signs. The
main clinical features consist of seizures
often preceding deep coma resulting from
cerebral edema, microhemorrhages, and
ischemia. Erythrocytes containing malaria
parasites accumulate in brain microvessels
where leucocytes and platelets are also
found.
The multi-factorial complexity of this
syndrome has been related to the para-
site’s release of glycosylphosphatidyl-inosi-
tol, which binds to pattern recognition
receptors, triggering an inflammatory re-
sponse and cytokine/chemokine release.
TNFa upregulates the endothelial inter-
cellular adhesion molecule ICAM, en-
hancing binding of parasitized erythro-
cytes to vascular endothelia with eventual
disruption of the blood–brain barrier
(BBB) [2]. This may result in activation
of microglial cells and astrocytes, demye-
lination, and/or neuronal injury [3].
Important insights have come from clini-
cal studies, post-mortem analyses of brains
from CM victims, in vitro studies of the
adhesion of parasitized erythrocytes to
brain endothelial cells, and genetic studies
of susceptibility and resistance determi-
nants in mice and humans [3]. Balanced
views on other aspects of CM pathogenesis
and pathophysiology, including metabolic
acidosis and capillary dysfunction, have
been discussed by Idro et al. [1], who
proposed renaming CM as ‘‘malaria with
neurological involvement’’, which leads to
long-term neurological sequels and/or
behavioral problems in 24% of cases,
imposing a major burden on African
children.
Although CM is associated with a
dramatic activation of brain endothelial
cells, with increased expression of ICAM
(see [2,3] for review), remarkably it does
not exhibit perivascular infiltrates, and no
transendothelial migration of leucocytes
occurs. Thus, in CM, inflammation and
immune-mediated events remain essential-
ly intravascular, in contrast to other
neuroimmunological disorders, such as
multiple sclerosis, which is characterized
by perivascular infiltrates and no intravas-
cular sequestration of leucocytes. Further-
more, the Plasmodium-infected erythrocytes
also remain intravascular, in contrast to
the direct CNS invasion by other patho-
gens, such as in toxoplasmosis. Conse-
quently, unless marked hemorrhages oc-
cur, there is a limited involvement of
parasites or of leucocytes within the CNS
parenchyma itself. It is not possible,
however, to draw conclusions about a lack
of inflammatory pathogenesis, because
most, if not all, brain pathology is
mediated by intravascular inflammatory
events. Concerted interdisciplinary actions
are needed to reach a better understand-
ing of CM pathogenesis and the intricate
roles of parasite-derived toxins, proinflam-
matory cytokines, and adhesion molecules.
The discovery of increased numbers of
endothelial cell membrane–derived micro-
particles in the circulation during acute
CM raises the question of their pathogenic
role, as suggested by disease protection in
mice lacking one of the genes controlling
microparticle formation [4].
Deciphering the precise host immune
responses associated with micro-environ-
mental alterations leading to CM is crucial
for devising novel therapeutic strategies.
Treatment compounds need to be simple,
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those recently described in model systems
[5,6]. Current treatment options tackle the
parasite but not the host response. Since
immunopathology participates in the path-
ogenesis of CM, new therapeutic ap-
proaches, aiming at a down-modulation
of excessive host responses, are desirable.
Human African
Trypanosomiasis
Human African trypanosomiasis
(HAT), or sleeping sickness, is caused by
subspecies of Trypanosoma brucei (Tb) trans-
mitted by tsetse flies. Although it was
nearly eliminated by the 1960s,, HAT has
re-emerged as an important threat, with
37,385 reported cases in sub-Saharan
Africa in 1998 [7]. However, the estimated
number of cases may be ten times as
many, although the number of newly
detected cases has been declining during
the last decade. The West African form is
caused by Tb gambiense, with humans as the
primary host and main reservoir, while the
East African form is caused by Tb
rhodesiense, with wild game or cattle as
primary hosts. Both diseases are lethal
when untreated, but their temporal profile
differs; the West African form lasts several
months or even years, whereas the East
African form progresses more rapidly [8].
The widely used card agglutination test for
screening of trypanosomiasis is only appli-
cable to Tb gambiense infections but is not
sufficiently sensitive or specific to be
diagnostic [7].
How do the parasites cross the BBB and
how does this passage relate to efficacy of
drug treatment? Can parasites ‘‘hide’’ in
the brain parenchyma behind the BBB
before relapses occur in unsuccessfully
treated patients? How do these extracellu-
lar parasites cause the severe neurological
symptoms that are manifested most con-
spicuously in disrupted sleep patterns [9]?
Are brain dysfunctions the cause of death
in HAT? These questions are important
for treatment. Although drugs are rela-
tively effective in curing both forms of
HAT early in infection, at later stages,
when most patients seek medical help,
only drugs that can have severe toxic side
effects, such as the widely used arsenic
compound melarsoprol, are available.
There is, therefore, an urgent need for
improving surveillance and diagnostic
tools to identify early HAT infection in
the field, as well as for new, nontoxic drugs
designed to cure brain infections. These
issues can be addressed by characterizing
the molecules involved in trafficking of
trypanosomes across the BBB and the
effects on brain functions of molecules
released during parasite–immune cell in-
teractions. The strategy of ‘‘new use for
old drugs’’, i.e., prescriptions for neglected
diseases of drugs marketed for other
illnesses [10], should also be pursued to
identify less toxic drugs to cure brain
infections.
A new sensitive, specific, and affordable
diagnostic test is needed for use in
countries where HAT is endemic. Early
detection and treatment with better drugs,
in combination with improved vector
control, will markedly reduce, if not
eliminate, the most prevailing West Afri-
can form of HAT.
Human American
Trypanosomiasis
For Trypanosoma cruzi, which causes
American trypanosomiasis or Chagas dis-
ease, there have been major advances in
its control in most Latin American coun-
tries where this infection was endemic in
the past 20 years. This has been achieved
by large-scale programs to halt transmis-
sion by eliminating populations of insect
vectors (the blood-feeding ‘‘assassin bugs’’,
sub-family Triatominae), screening of blood
donors and Chagasic mothers. According
to the World Health Report 2004 [11], the
disability adjusted life years for Chagas
disease were 667,000 and the number of
yearly deaths was 14,000 (compared with
estimates for HAT of 1,525,000 and
48,000, respectively). Non-treated, the
disease evolves in a slow and progressive
way into autonomic system neuropathies
causing fatal cardiomyopathy and mega-
colon syndromes in about 30% of the
patients. Involvement of the CNS is
infrequent, discrete, and non-specific, but
in AIDS patients, meningo-encephalitis
with parasites in glial cells has been
documented [12]. A parasite-derived neu-
rotropic factor that binds to the high-
affinity receptor for nerve growth factor
TrkA (tropomyosin-related kinase A) may
be involved in the pathogenesis of nervous
system infection [13]. Reaching an inter-
national consensus on diagnostic and
treatment procedures is a current priority.
HIV-Associated Dementia and
Neurocognitive Disorders
HIV can spread to the CNS during
early and late disease stages, leading to
HIV-associated dementia (HAD) or HIV-
associated neurocognitive disorders
(HAND). In the Western world, where
HIV clade B dominates, the advent of
highly active anti-retroviral therapy has
reduced the incidence of HAD and
HAND by approximately half (,15%).
The neurobiological basis of these condi-
tions is not due to direct HIV infection of
neurons, but to synapto-dendritic alter-
ations called ‘‘beading’’ [14]. Cortical
motoneurons and interneurons that show
these alterations may eventually die of
apoptosis.
In sub-Saharan Africa, where AIDS is
prevalent, HAD incidence was studied
recently using an accurate, cross-cultural
HAD scale [15]. In Uganda, where clades
D and A dominate, 31% of AIDS patients
develop HAD, which can affect verbal
memory, fine and gross motor perfor-
mances, psychomotor speed, and execu-
tive functions. Affected individuals have a
higher rate of unemployment than con-
trols and show poor performance in daily
family life. In contrast, in Ethiopia where
HIV clade C dominates, only minor
cognitive alterations were reported in
AIDS patients. The lesser impact of HIV
on cognitive functions in this case could be
explained by the poor ability of HIV clade
C isolates to grow in macrophages, a
characteristic of neurotropic strains.
Some envelope glycoprotein variants
(named N283) are more frequently isolat-
ed from infected brains than from other
organs [16]. These variants were likely
selected by their ability to bind to low
levels of the HIV receptor CD4 and co-
receptor CCR5 on perivascular macro-
phages and microglia residing in the CNS.
Viral replication in these target cells results
in the formation of multinucleated cells.
Such giant cells also produce virus that will
further spread and persist in the brain
where HIV protease inhibitors have lim-
ited accessibility. Clearing such a viral
reservoir would require specific inhibitors
for neurotropic variants that can cross the
BBB [17].
More epidemiological studies of HAD
and HAND should determine the impact
of HIV infection on brain function in
different regions of sub-Saharan Africa.
To decrease the negative impact of these
syndromes on patient cognitive behavior
and improve societal acceptance of indi-
viduals with HAD or HAND, one needs to
isolate and characterize neurotropic viral
subtypes from the cerebrospinal fluid early
in AIDS. This might allow designing ways
to block HIV entry into the CNS.
Emerging Infectious Diseases of
the CNS
Viral encephalitis is emerging or re-
emerging as an important cause of human
disease due to increased geographic range
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litis virus) or new spread of viruses from
animal reservoirs into human populations
(e.g., Nipah and Hendra viruses) [18,19].
According to the World Health Organi-
zation, Japanese encephalitis is the leading
cause of viral encephalitis in Asia, with an
annual incidence of 30,000–50,000 clinical
cases. Changes in vector populations and
in human association with reservoir hosts,
and the appearance of new viral variants
that are more virulent for humans or more
efficiently transmitted, are associated with
emerging viruses, half of which cause
serious neurological diseases [20].
Arthropod-borne viruses have been
restricted in range geographically by the
availability of their invertebrate and ver-
tebrate hosts. However, modern transpor-
tation has introduced vectors that effi-
ciently transmit arboviruses into new areas
(e.g., the Asian tiger mosquito Aedes
albopictus into North America and Europe).
In many areas, pre-existing populations of
competent vectors set the stage for suc-
cessful establishment of viruses in new
regions. Recent examples are the intro-
duction of West Nile virus into North
America, where susceptible vectors and
hosts were abundant and rapid spread
across the continent has resulted in more
than 11,000 cases of CNS disease, and the
arrival of a strain of Chikungunya virus
adapted to Ae. albopictus in southern
Europe. West Nile virus has the widest
distribution of all flaviviruses, its range
spanning Africa, North, Central, and
South America, West Asia, Europe, the
Middle East, and Australia [18]. Japanese
encephalitis and Rift Valley fever viruses
could easily follow the same pattern.
Bats are increasingly recognized as
important hosts for a number of zoonoses
that cause CNS infection (e.g., lyssa-
viruses, henipaviruses, coronaviruses, and
filoviruses). Disruption of the environment
with changing agricultural practices has
increased the likelihood that these viruses
will be transmitted to humans, as suggest-
ed by Nipah and Hendra virus outbreaks.
New outbreaks of Nipah encephalitis, nine
of which have occurred in Bangladesh
since 2001, resulting in the death of 40%–
75% of infected people, indicate human-
to-human as well as bat-to-human trans-
mission [21].
There are currently no treatments
available for these viral CNS diseases.
Development of antiviral agents may be
useful, but treatment at the time of
symptoms may not be effective. Vaccines
are likely to be the most effective inter-
ventions and are available or in develop-
ment for many of these viruses (viz.,
Japanese encephalitis, tick-borne enceph-
alitis, and West Nile); however, to be
effectively utilized, spread of the virus
must be monitored and disease outbreaks
anticipated.
Perspectives
There is an urgent need for continued
surveillance and identification of viruses in
vertebrate and invertebrate hosts to antic-
ipate the introduction and spread of new
and old agents. A better understanding of
the mechanisms of entry into the CNS, of
neuronal damage, the immune response to
virus infection, and prevention of CNS
infection will guide the development of
appropriate interventions.
The questions raised here are part of a
broader field of investigations on a dozen
neurotropic pathogens that were discussed
at a September 2008 conference in Paris,
‘‘Infections of the Nervous System: Path-
ogenesis and World Impact’’. This confer-
ence has addressed the current gaps in
knowledge and set the stage to establish an
agenda for confronting this group of
diseases in the coming years. Abstracts
have been published in BMC Proceedings
([22]; http://www.biomedcentral.com/
1753-6561/2?issue=S1). We need to in-
crease the awareness of the world’s leading
institutions on the impact and challenges
in this field and to foster new research and
training programs that will trigger new
ideas to study the mechanisms of pathogen
spreading and neural cell dysfunction in
close contact with clinical research and
surveillance, diagnosis, and treatment of
infectious neurological diseases. Progress
will depend on the development of a
systemic approach based on cross-fertil-
ization between clinicians studying disease
mechanisms and scientists working on the
life cycle and molecular makeup of
neurotropic infectious agents and their
vectors; between immunologists studying
innate and adaptive immune responses to
neurotropic pathogens and cell biologists
investigating pathogen interactions with
the BBB and neural cells; and between
leaders in new technologies for diagnosis
and therapies and medical anthropolo-
gists.
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